SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: former_pgs who wrote (1891)2/7/2005 9:13:35 PM
From: IRWIN JAMES FRANKEL  Read Replies (1) of 12215
 
I had written this privately to zeta, but it fits so well with pgs's comments that I will post it:

The problem with Iressa is that toxicity builds up too rapidly and often before EGFRi reaches theraputic levels.

Tarceva is better as is Erbitux because they reach theraputic levels with lower tox. I would look for both of these to eat away at Iressa EVEN if it is left on the market. (I would favor leaving it on the market from a science point of view.) AZN may pull it regardless. It will never make them money and could cause legal exposure.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News